Century Therapeutics Stock (NASDAQ: IPSC)

Century Therapeutics

CENTURY THERAPEUTICS INC

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Nassau,,Bahamas,-,February,9,,2023:,The,Bahamas,Was,Pounded

News

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

ALNY

CNXC

IPSC

LITE

PINS

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday

Balancing Safe And Risky Investments

Equities

Markets

Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%

Kazan,,Russia,-,Oct,19,,2021:,Robinhood,Markets,Is,An

CSCO

DELL

HOOD

SNOW

Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday

Century Therapeutics, Inc. - Common Stock

Century Therapeutics Inc

Management

Press Releases

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Earnings

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Clear Street Launches Healthcare & Biotechnology Equity Research

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

Health Care

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

JANX

MLTX

NUVB

PTGX

YMAB

Adicet Bio

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Avalo Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech

Forte Biosciences

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Opus Genetics

Kronos Bio

Lantern Pharma

Mural Oncology

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Renovaro

Shattuck Labs

HC Wainwright & Co.

Chardan Capital

Piper Sandler

Canaccord Genuity

JP Morgan

Comments

Century Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell